These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF Arthritis Rheum; 2011 Nov; 63(11):3439-47. PubMed ID: 21702020 [TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease in polymyositis and dermatomyositis. Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835 [TBL] [Abstract][Full Text] [Related]
5. Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Tomonaga M; Sakamoto N; Ishimatsu Y; Kakugawa T; Harada T; Nakashima S; Hara A; Hara S; Horai Y; Kawakami A; Mukae H; Kohno S Lung; 2015 Feb; 193(1):79-83. PubMed ID: 25394672 [TBL] [Abstract][Full Text] [Related]
6. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Zamora AC; Hoskote SS; Abascal-Bolado B; White D; Cox CW; Ryu JH; Moua T Respir Med; 2016 Sep; 118():39-45. PubMed ID: 27578469 [TBL] [Abstract][Full Text] [Related]
7. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. La Corte R; Lo Mo Naco A; Locaputo A; Dolzani F; Trotta F Autoimmunity; 2006 May; 39(3):249-53. PubMed ID: 16769659 [TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Tillie-Leblond I; Wislez M; Valeyre D; Crestani B; Rabbat A; Israel-Biet D; Humbert M; Couderc LJ; Wallaert B; Cadranel J Thorax; 2008 Jan; 63(1):53-9. PubMed ID: 17557770 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. Jiang M; Dong X; Zheng Y Medicine (Baltimore); 2021 May; 100(19):e25816. PubMed ID: 34106621 [TBL] [Abstract][Full Text] [Related]
11. [Clinical features and misdiagnosis of anti-Jo-1 syndrome: analysis of 33 cases]. Zheng WJ; Wei W; Tang FL Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1565-8. PubMed ID: 14642109 [TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome. Yang H; Chen Q; Sun C; Jin Q; Zhang L; Liu Q; Peng Q; Wang G; Lu X Respir Res; 2024 May; 25(1):222. PubMed ID: 38811943 [TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Mielnik P; Wiesik-Szewczyk E; Olesinska M; Chwalinska-Sadowska H; Zabek J Autoimmunity; 2006 May; 39(3):243-7. PubMed ID: 16769658 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic options in anti-jo-1 antisynthetase syndrome with interstitial lung disease: comment on the article by Marie et al. Cavagna L; Caporali R Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1548. PubMed ID: 23554341 [No Abstract] [Full Text] [Related]
19. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573 [TBL] [Abstract][Full Text] [Related]